Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.
Carcinoma|Cervix Carcinoma
DRUG: Karelizumab combined with etoposide and cisplatin
Objective Response Rate, The proportion of participants achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to RECIST1.1., 6-month
Progression-free survival, The period between the onset of treatment and the observation of disease progression or the occurrence of death for any reason., 6-month|Disease-free survival period, After radical treatment (complete surgical removal of the tumor), there is no time for the disease to recur., 6-month|1 year and 3 year overall survival rates, The proportion of patients who have survived for one and three years after comprehensive treatment., 1 year and 3 year|1-year and 3-year progression free survival rates, The probability that the patient's disease will not continue to worsen within one and three years., 1 year and 3 year|1-year and 3-year disease control rates, The proportion of patients with reduced or stable tumors within 1 and 3 years., 1 year and 3 year|Incidence rate of adverse events, The ratio of the number of cases with adverse events to the total number of cases available for evaluation., 5 years|Disease control rate, The proportion of participants achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to RECIST1.1., 6-month
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.Following this, patients achieving complete or partial response will proceed to radical surgery and adjuvant therapy, while those with stable or progressive disease, or considered unsuitable for surgery by gynecological oncologists, will transfer to concurrent chemoradiotherapy.